Plasma cell myeloma
Not recruitingStudy Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
- Disease:Plasma cell myeloma
- Substances:Belantamab MafodotinDaratumumab+3
Belgium- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Glaxosmithkline Research & Development Limited











